Results 11 to 20 of about 57,075 (302)

Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain

open access: yesJournal of Pain Research, 2015
Ish K Khanna, Sivaram PillarisettiNeuroPn Therapeutics, Alpharetta, GA, USAAbstract: Despite proven clinical utility, buprenorphine has not been used widely for the treatment of chronic pain.
Khanna IK, Pillarisetti S
doaj   +1 more source

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use

open access: yesAddiction Science & Clinical Practice, 2023
Background We use a novel, longitudinal approach to describe average time spent in opioid use disorder (OUD) cascade of care stages for people with HIV (PWH) and with OUD, incorporating four definitions of treatment retention.
Jarratt D. Pytell   +7 more
doaj   +1 more source

Buprenorphine Waiver Attitudes Among Primary Care Providers

open access: yesJournal of Primary Care & Community Health, 2022
Background: Despite efforts to improve access to Medications for Opioid Use Disorder (MOUD), such as buprenorphine, the number of opioid overdoses in the United States continues to rise.
Benjamin Lai   +2 more
doaj   +1 more source

Emergency Department Buprenorphine Quality Improvement and Emergency Physician Knowledge, Attitudes, and Self-Efficacy

open access: yesWestern Journal of Emergency Medicine, 2023
Objective: Buprenorphine is an evidence-based treatment for opioid use disorder that is underused in the emergency department (ED). In this study we evaluated changes in emergency physician knowledge, confidence, and self-efficacy regarding buprenorphine
Michelle L. Myles   +5 more
doaj   +1 more source

A comparative study of intrathecal and epidural buprenorphine using combined spinal-epidural technique for caesarean section

open access: yesIndian Journal of Anaesthesia, 2010
Neuraxial opioids provide excellent analgesia intraoperatively and postoperatively while allowing early ambulation of the patient by sparing sympathetic and motor nerves. A prospective, randomised double blind study was conducted involving 90 patients of
Shaloo Ipe   +5 more
doaj   +1 more source

Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs

open access: yesSubstance Abuse Treatment, Prevention, and Policy, 2022
Background and aims In the United States, access to buprenorphine remains low and disparities regarding who receives treatment have emerged. Federal laws have regulated buprenorphine delivery, ultimately limiting its implementation more broadly.
Barrot H. Lambdin   +2 more
doaj   +1 more source

Adapting low-dose buprenorphine induction to meet patient needs: A pilot study

open access: yesDrug and Alcohol Dependence Reports, 2022
Introduction: Low-dose buprenorphine induction (LDBI) has been proposed to initiate buprenorphine in patients who are taking full opioid agonists in order to limit the risk of precipitated withdrawal.
Zoe A. Karavolis, Payel J. Roy
doaj   +1 more source

Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements. [PDF]

open access: yesMilbank Q
Policy Points States contract with Medicaid managed care plans to administer benefits for roughly 70 million Medicaid enrollees, yet little is known about how plan benefit policies for substance use disorder (SUD) treatment medications align with state requirements.
Feltus SR   +6 more
europepmc   +2 more sources

Safety of opioid patch initiation in Australian residential aged care [PDF]

open access: yes, 2015
Explores opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Abstract Objective: To explore opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Design:
Lisa Pont   +5 more
core   +1 more source

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men [PDF]

open access: yesAddiction and Health, 2018
Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of ...
Hassan Ziaaddini   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy